Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: A cost-utility analysis

Value in Health

Volumn 15, Issue 5, 2012, Pages 759-770

  Woods, Beth ^a   Hawkins, Neil ^a   Dunlop, William ^b   O'Toole, Alison ^c   Bramham Jones, Steve ^c  

^a ICON PLC   (United Kingdom)

^b Mundipharma International Limited   (United Kingdom)

^c Napp Pharmaceuticals Limited   (United Kingdom)

Author keywords

bendamustine; chlorambucil; chronic lymphocytic leukemia; cost effectiveness; cost utility; QALY

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CHLORAMBUCIL; CODEINE; CYCLOPHOSPHAMIDE; DOMPERIDONE; ERYTHROPOIETIN; FLUDARABINE; LOPERAMIDE; METOCLOPRAMIDE; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CYTOPENIA; DIARRHEA; FEVER; HEALTH CARE COST; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; VOMITING;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHLORAMBUCIL; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; ENGLAND; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MARKOV CHAINS; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NITROGEN MUSTARD COMPOUNDS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; WALES;

EID: 84864589386     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.03.1389     Document Type: Article

References (36)

1. F. Schriever, D. Huhn New directions in the diagnosis and treatment of chronic lymphocytic leukaemia Drugs 63 2003 953 969
2. Cancer Research UK Latest UK cancer incidence and mortality summary. June 2011 http://info.cancerresearchuk.org/cancerstats/incidence/index.htm [Accessed June 16, 2011]
3. D. Oscier, C. Fegan, P. Hillmen British Committee for Standards in Haematology Guidelines on the diagnosis and management of chronic lymphocytic leukaemia Br J Haematol 125 2004 294 317
4. P. Hillmen Chronic lymphocytic leukaemia - moving towards cure? Lancet 376 2010 1122 1123
5. D. Catovsky, S. Richards, E. Matutes Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 2007 230 239
6. W.U. Knauf, T. Lissichkov, A. Aldaoud Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia J Clin Oncol 27 2009 4378 4384
7. National Institute for Health and Clinical Excellence Bendamustine for the first-line treatment of chronic lymphocytic leukaemia NICE Technology Appraisal Guidance 216: February 2011 http:// www.nice.org.uk/nicemedia/live/ 13343/53180/53180.pdf [Accessed June 16, 2011]
8. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal http://www.nice.org.uk/aboutnice/howwework/ devnicetech/technologyappraisalprocessguides/ guidetothemethodsoftechnologyappraisal.jsp [Accessed June 16, 2011]
9. Napp Pharmaceuticals Limited Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate http://guidance.nice. org.uk/TA/Wave23/16/FAD/ManufacturerSubmissionNapp/pdf/English [Accessed June 17, 2011]
10. B.D. Cheson, J.M. Bennett, M. Grever National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 1996 4990 4997
11. B.D. Cheson, J.M. Bennett, K.R. Rai Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group Am J Hematol 29 1988 152 163
12. D. Collet Modelling Survival Data in Medical Research 2003 Chapman & Hall/CRC Boca Raton, FL
13. H. Putter, M. Fiocco, R.B. Geskus Tutorial in biostatistics: competing risks and multi-state models Statist Med 26 2007 2389 2430
14. T. Robak, J.Z. Blonski, M. Kasznicki The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil Haematologica 90 2005 994 996
15. T. Robak, A. Dmoszynska, P. Solal-Céligny Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia J Clin Oncol 28 2010 1756 1765
16. K. Beusterien, J. Davies, M. Leach Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study Health Qual Life Outcomes 8 2010 50
17. L. McKenzie, M. van der Pol Mapping the EORTC QLQ-C30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data Value Health 12 2009 167 171
18. M.M. Versteegh, D. Rowen, J.E. Brazier, E.A. Stolk Mapping onto EQ-5D for patients in poor health Health Qual Life Outcomes 8 2010 141
19. British National Formulary 59 2010 BMJ Group/Pharmaceutical Press London
20. Department of Health NHS reference costs 2008-09 http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-s111591 [Accessed June 17, 2011]
21. J. Herrstedt, F. Roila Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis Ann Oncol 20 2009 iv156 iv158
22. NHS Blood and Transplant NHS Blood and Transplant Annual Review 2008-2009 http://www.nhsbt.nhs.uk/annualreview/pdf/?docid=100920094926- 5fd8f2f628894d758ae5fa413e38448a&issue=2008-2009&pdf= nhsbt-annual-review-2008-2009 [Accessed June 17, 2011]
23. J. Wilson, G.L. Yao, J. Raftery A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment Health Technol Assess 11 2007 1 202 iii-iv
24. E. Montserrat, A. Alcalá, R. Parody Treatment of chronic lymphocytic leukaemia in advanced stages: a randomised trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine and prednisone Cancer 56 1985 2369 2375
25. S. O'Brien, H. Kantarjian, J. Corles Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukaemia J Clin Oncol 19 2001 1414 1420
26. National Institute for Health and Clinical Excellence Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia NICE Technology Appraisal Guidance 119: February 2007 http://www.nice.org.uk/ nicemedia/live/11614/33943/33943.pdf [Accessed June 17, 2011]
27. National Institute for Health and Clinical Excellence Rituximab for the first-line treatment of chronic lymphocytic leukaemia NICE Technology Appraisal Guidance 174: July 2009 http://www.nice.org.uk/nicemedia/live/11907/44906/44906. pdf [Accessed June 17, 2011]
28. M. Hallek, K. Fischer, G. Fingerle-Rowson Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
29. C.S. Tam, S. O'Brien, W. Wierda Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 2008 975 980
30. M.J. Keating, S. O'Brien, S. Lerner Early results of a chemoimmuno-therapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 23 2005 4079 4088
31. F. Bosch, A. Ferrer, N. Villamor Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication Clin Cancer Res 14 2008 155 161
32. W.U. Knauf, T. Lissichkov, A. Aldaoud Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukaemia Blood (ASH annual meeting abstracts) 116 2010 2449
33. Scottish Medicines Consortium Advice on bendamustine hydrochloride 25 mg, 100 mg powder for infusion (Levact®) http://www.scottishmedicines.org.uk/ files/advice/bendamustine-Levact-CLL-FINAL-MARCH-2011-for-website.pdf March 2011 [Accessed July 18, 2011]
34. K.S. Panageas, L. Ben-Porat, M.N. Dickler When you look matters: the effect of assessment schedule on progression-free survival J Natl Cancer Inst 99 2007 428 432
35. M. Hoyle, C. Crathorne, T. Jones-Hughes, K. Stein Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination therapy is not appropriate: a critique of the submission from Napp http://www.nice.org.uk/nicemedia/live/12970/52241/ 52241.pdf [Accessed June 17, 2011]
36. J.P. Morden, P.C. Lambert, N. Latimer Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study BMC Med Res Meth 11 2011 4